Captrust Financial Advisors Decreases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Captrust Financial Advisors lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 75.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,562 shares of the biopharmaceutical company's stock after selling 22,765 shares during the period. Captrust Financial Advisors' holdings in TG Therapeutics were worth $228,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of TGTX. Barclays PLC raised its position in TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of TG Therapeutics by 52.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company's stock worth $244,000 after buying an additional 2,803 shares during the period. Daymark Wealth Partners LLC increased its stake in TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after buying an additional 689 shares during the period. Avaii Wealth Management LLC lifted its holdings in shares of TG Therapeutics by 4.9% in the 4th quarter. Avaii Wealth Management LLC now owns 30,393 shares of the biopharmaceutical company's stock valued at $915,000 after buying an additional 1,409 shares during the period. Finally, Kingswood Wealth Advisors LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth $228,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Up 1.9%

TGTX traded up $0.67 during trading on Tuesday, hitting $35.24. The company had a trading volume of 1,286,460 shares, compared to its average volume of 2,983,122. The company has a market capitalization of $5.59 billion, a PE ratio of -352.36 and a beta of 2.21. The firm's 50-day moving average price is $37.84 and its 200 day moving average price is $34.36. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.07) EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on TGTX shares. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.